FUJIFILM Diosynth Biotechnologies is investing US$2 billion to open new large-scale cell culture manufacturing facility in North Carolina, USA.
The upcoming facility will emerge as the Contract Development and Manufacturing Organisation (CDMO), boasting cutting-edge biopharmaceutical manufacturing equipment and technology.
The facility's scale is emphasized by the inclusion of two expansive manufacturing suites, each equipped with 4 x 20,000 L bioreactors.
This facility has been designed with future scalability in mind, spanning an area of nearly 1,000,000 square feet. Its adaptability allows seamless expansion, accommodating the integration of an additional 24 x 20,000 L bioreactors to cater to upcoming projects.
Once operational, this site will serve as a comprehensive hub offering drug substance manufacturing, automated fill-finish and assembly, as well as packaging and labelling services to the global biopharmaceutical domain.
Moreover, this site is set to be a significant job creator, aiming to generate 725 manufacturing jobs in North Carolina by the end of 2028.
Name FUJIFILM Diosynth Biotechnologies
Type New Construction
Budget US$2 billion